文献速递细胞病理与分子病理

Afirma基因测序分类器与基因表达分类器诊断性能比较的meta分析

Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis.
PubMed 文献 · Cancer Cytopathol · 2020-07-29

该meta分析纳入7项研究,比较Afirma基因测序分类器(GSC)与基因表达分类器(GEC)在甲状腺结节细针穿刺(FNA)不确定细胞学中的诊断性能。结果显示GSC的良性检出率更高(65.3% vs 43.8%,P<.001),手术切除率更低(26.8% vs 50.1%,P<.001),恶性风险更高(60.1% vs 37.6%,P<.001),且特异度(43.0% vs 25.1%,P=.003)和阳性预测值(63.1% vs 41.6%,P=.004)显著改善,同时保持高灵敏度(94.3%)和高阴性预测值(90.0%)。

要点

  • GSC较GEC显著提高良性检出率(65.3% vs 43.8%,P<.001),降低手术切除率(26.8% vs 50.1%,P<.001)。
  • GSC在嗜酸细胞为主结节中良性检出率显著提升(73.7% vs 21.4%,P<.001)。
  • GSC特异度(43.0% vs 25.1%,P=.003)和阳性预测值(63.1% vs 41.6%,P=.004)显著改善,灵敏度94.3%,阴性预测值90.0%。

核心结论

  • GSC较GEC具有更高的良性检出率和更优的诊断性能,可减少不必要的手术干预。

研究设计与样本

  • Meta分析,检索PubMed和Web of Science,纳入7项研究,比较GSC与GEC的良性检出率、切除率、恶性风险、灵敏度、特异度、阳性预测值和阴性预测值。

主要发现

  • GSC的良性检出率为65.3%,GEC为43.8%(P<.001)。
  • GSC的切除率为26.8%,GEC为50.1%(P<.001)。
  • GSC的恶性风险为60.1%,GEC为37.6%(P<.001)。
  • 嗜酸细胞为主结节的良性检出率GSC为73.7%,GEC为21.4%(P<.001)。
  • GSC特异度43.0% vs GEC 25.1%(P=.003),阳性预测值63.1% vs 41.6%(P=.004),灵敏度94.3%,阴性预测值90.0%。

关键数值与推荐

  • GSC良性检出率65.3%,切除率26.8%,恶性风险60.1%,特异度43.0%,阳性预测值63.1%,灵敏度94.3%,阴性预测值90.0%。
  • GEC良性检出率43.8%,切除率50.1%,恶性风险37.6%,特异度25.1%,阳性预测值41.6%。
  • 嗜酸细胞为主结节良性检出率GSC 73.7%,GEC 21.4%(P<.001)。

临床怎么用

  • 对于细胞学不确定的甲状腺FNA患者,GSC可提高良性检出率并降低不必要的手术。
  • GSC改善的特异度和阳性预测值有助于更精准地筛选需手术的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Afirma microarray-based Gene Expression Classifier (GEC) with its high negative predictive value (NPV) and sensitivity has been used to rule out cancer from thyroid nodules with an indeterminate cytology but not to rule in cancer because of its low positive predictive value (PPV) and specificity. The Gene Sequencing Classifier (GSC) has been reported to improve on the weakness of GEC. In this study, a meta-analysis was performed to compare the clinical impact and diagnostic performance of GEC and GSC. Relevant data were searched in PubMed and Web of Science. Meta-analyses for proportion and dichotomous outcomes were performed to compare the benign call rates (BCRs), resection rates (RRs), risks of malignancy (ROMs), sensitivities, specificities, PPVs, and NPVs of GSC and GEC. Seven studies were included for the meta-analyses. Compared with GEC, GSC had a higher BCR (65.3% vs 43.8%; P < .001), a lower RR (26.8% vs 50.1%; P < .001), and a higher ROM (60.1% vs 37.6%; P < .001). The BCR of Hürthle cell-predominant nodules was significantly elevated (73.7% vs 21.4%; P < .001). In addition, the specificity (43.0% vs 25.1%; P = .003) and PPV (63.1% vs 41.6%; P = .004) of Afirma GSC were significantly improved while it still maintained a high sensitivity (94.3%) and a high NPV (90.0%). In conclusion, this study confirms and highlighted the clinical and diagnostic significance of GSC. With an increased BCR and improved diagnostic performance, GSC could reduce the rate of unnecessary surgical interventions and better tailor the clinical decisions of patients with indeterminate thyroid fine-needle aspiration results.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Vuong HG, Nguyen TPX, Hassell LA, et al. Diagnostic performances of the Afirma Gene Sequencing Classifier in comparison with the Gene Expression Classifier: A meta-analysis. Cancer Cytopathol. 2020. PMID: 32726885. doi:10.1002/cncy.22332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。